SARS-CoV-2 3CLpro-IN-21_product_DataBase

CAS: F: C14H10BrN3O2S W: 364.22

SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CLpro with an IC50 of 0.03 μM. S

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CLpro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CLpro with an IC50 of 0.12μM[1].
Target	0.03 μM (3CLpro)
Name	SARS-CoV-2 3CLpro-IN-21
Formula	C14H10BrN3O2S
Molar Mass	364.22
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhang FM, et al. Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19. Eur J Med Chem. 2023 Nov 15;260:115721.

PeptideDB